A 16-year bicentric retrospective analysis of ovarian tissue cryopreservation in pediatric units: indications, results, and outcome.
children cancer
fertility preservation
follow up
gonadotoxic treatment
ovarian tissue cryopreservation
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
02
2023
accepted:
09
08
2023
medline:
19
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Cancer treatments of the last decades improve the survival rate of children and adolescents. However, chemo- and radiotherapy result in gonadal damage, leading to acute ovarian failure and sterility. The preservation of fertility is now an integral part of care of children requiring gonadotoxic treatments. Ovarian tissue cryopreservation (OTC) is an effective fertility preservation option that allows long-term storage of primordial follicles, subsequent transplantation, and restoration of endocrine function and fertility. The efficacy of this technique is well-demonstrated in adults but the data are scarce for pediatric patients. Currently, OTC represents the only possibility of preserving the potential fertility in prepubertal girls. This is a retrospective study of OTC practice of two French centers from January 2004 to May 2020. A total of 72 patients from pediatric units underwent cryopreservation of ovarian tissue before gonadotoxic therapy for malignant or non-malignant diseases. The ovarian cortex was cut into fragments and the number of follicles per square millimeter was evaluated histologically. The long-term follow-up includes survival rate and hormonal and fertility status. The mean age of patients at OTC was 9.3 years [0.2-17] and 29.2% were postpubertal; 51 had malignant diseases and 21 had non-malignant diseases. The most frequent diagnoses included acute leukemia, hemoglobinopathies, and neuroblastoma. Indication for OTC was stem cell transplantation for 81.9% ( OTC should be proposed to all girls with high risk of developing POI following gonadotoxic therapies in order to give them the possibility of fertility and endocrine restoration.
Sections du résumé
Background
Cancer treatments of the last decades improve the survival rate of children and adolescents. However, chemo- and radiotherapy result in gonadal damage, leading to acute ovarian failure and sterility. The preservation of fertility is now an integral part of care of children requiring gonadotoxic treatments. Ovarian tissue cryopreservation (OTC) is an effective fertility preservation option that allows long-term storage of primordial follicles, subsequent transplantation, and restoration of endocrine function and fertility. The efficacy of this technique is well-demonstrated in adults but the data are scarce for pediatric patients. Currently, OTC represents the only possibility of preserving the potential fertility in prepubertal girls.
Procedure
This is a retrospective study of OTC practice of two French centers from January 2004 to May 2020. A total of 72 patients from pediatric units underwent cryopreservation of ovarian tissue before gonadotoxic therapy for malignant or non-malignant diseases. The ovarian cortex was cut into fragments and the number of follicles per square millimeter was evaluated histologically. The long-term follow-up includes survival rate and hormonal and fertility status.
Results
The mean age of patients at OTC was 9.3 years [0.2-17] and 29.2% were postpubertal; 51 had malignant diseases and 21 had non-malignant diseases. The most frequent diagnoses included acute leukemia, hemoglobinopathies, and neuroblastoma. Indication for OTC was stem cell transplantation for 81.9% (
Conclusion
OTC should be proposed to all girls with high risk of developing POI following gonadotoxic therapies in order to give them the possibility of fertility and endocrine restoration.
Identifiants
pubmed: 37720539
doi: 10.3389/fendo.2023.1158405
pmc: PMC10501795
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1158405Informations de copyright
Copyright © 2023 Grellet-Grün, Delepine, Le Van Quyen, Avérous, Durlach, Greze, Ladureau-Fritsch, Lichtblau, Canepa, Liné, Paillard, Pluchart, Pirrello, Rongieres, Harika, Becmeur and Teletin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Minim Invasive Gynecol. 2020 Sep - Oct;27(6):1253
pubmed: 31838276
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17474-9
pubmed: 24082083
Front Endocrinol (Lausanne). 2022 Jun 29;13:930786
pubmed: 35846295
J Assist Reprod Genet. 2013 Jan;30(1):3-9
pubmed: 23242649
Pediatr Blood Cancer. 2007 Jul;49(1):74-8
pubmed: 16977608
Future Oncol. 2018 Feb;14(4):363-378
pubmed: 29345507
Hum Reprod. 2003 Jun;18(6):1158-64
pubmed: 12773440
Minerva Ginecol. 2018 Aug;70(4):432-435
pubmed: 29696941
Acta Obstet Gynecol Scand. 2020 Feb;99(2):213-221
pubmed: 31538662
J Clin Oncol. 2018 Jul 1;36(19):1994-2001
pubmed: 29620997
Reprod Biomed Online. 2020 Apr;40(4):547-554
pubmed: 32199797
Acta Obstet Gynecol Scand. 2019 May;98(5):630-637
pubmed: 30919447
Obstet Gynecol Int. 2012;2012:910698
pubmed: 22518166
Reprod Med Biol. 2021 May 12;20(3):277-288
pubmed: 34262395
Hum Fertil (Camb). 2016 Apr;19(1):23-31
pubmed: 27008573
Bull Acad Natl Med. 2013 Apr-May;197(4-5):887-98
pubmed: 25518157
Fertil Steril. 2021 May;115(5):1102-1115
pubmed: 33933173
Hum Reprod Update. 2010 Nov-Dec;16(6):617-30
pubmed: 20462941
Reproduction. 2019 Nov;158(5):F35-F44
pubmed: 31394506
Reproduction. 2019 Nov;158(5):F27-F34
pubmed: 31284266
J Pediatr Surg. 2019 Mar;54(3):543-549
pubmed: 30782317
J Pediatr Surg. 2007 May;42(5):862-4
pubmed: 17502200
Fertil Steril. 2009 Aug;92(2):458-63
pubmed: 18952208
Acta Obstet Gynecol Scand. 2019 May;98(5):604-615
pubmed: 30723910
Pediatr Blood Cancer. 2009 Aug;53(2):267-73
pubmed: 19301406
Front Endocrinol (Lausanne). 2022 Jun 10;13:918899
pubmed: 35774145
Hum Reprod. 2016 Apr;31(4):750-62
pubmed: 26848188
Hum Reprod. 2014 May;29(5):989-96
pubmed: 24522758
Front Endocrinol (Lausanne). 2022 Oct 12;13:1035109
pubmed: 36313739
Obstet Gynecol Int. 2012;2012:139193
pubmed: 22496695
Lancet Oncol. 2014 Sep;15(10):1129-36
pubmed: 25130994
Hum Reprod. 1996 Oct;11(10):2215-6
pubmed: 8943532
Hum Reprod. 2017 Jan;32(1):154-164
pubmed: 27816923
Science. 2019 Mar 15;363(6432):1182-1186
pubmed: 30872518